In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.

Volume 5, Issue 8

Conversations with key opintion leaders in the field of viral hepatitis. eViralHepatitis Review is a monthly CE certified newsletter and podcast series created speicifically for hepatologists, infectious disease specialists, PCPS, nurses and nurse practitioners.  Bi-monthly podcasts are also available as down-loadable transcripts, providing case-based scenarios to help bring that new clinical information into practice in the exam room and at the bedside. This program is presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.  Support is provided from a unrestricted educational grant from Gilead Sciences, Inc. and Vertex Pharmaceuticals.

Medicine

Conversations with key opintion leaders in the field of viral hepatitis. eViralHepatitis Review is a monthly CE certified newsletter and podcast series created speicifically for hepatologists, infectious disease specialists, PCPS, nurses and nurse practitioners. Bi-monthly podcasts are also available as down-loadable transcripts, providing case-based scenarios to help bring that new clinical information into practice in the exam room and at the bedside. This program is presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. Support is provided from a unrestricted educational grant from Gilead Sciences, Inc. and Vertex Pharmaceuticals.

Share Volume 5, Issue 8

Sign up to save your podcasts

Volume 5, Issue 8

Volume 5, Issue 8